<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 22, 2000 (December 4, 2000)
MEDAREX, INC.
(Exact name of registrant as specified in its charter)
New Jersey 0-19312 22-2822175
(State of other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
707 State Road, Ste. 206, Princeton, N.J. 08540-1437
(Address of Principal Executive Offices)
Registrant's telephone number, including area code: (609) 430-2880
Not Applicable
(Former name or former address, if changed since last report)
<PAGE>
MEDAREX, INC.
TABLE OF CONTENTS
FOR
CURRENT REPORT ON FORM 8-K
Item 5. Other Events...................................... 3
Item 7. Financial Statements and Exhibits................. 5
Signature...................................................... 6
-2-
<PAGE>
Item 5. Other Events.
On December 4, 2000, Medarex, Inc., a New Jersey corporation (the
"Company"),and Aventis Behring L.L.C. announced positive results from a Phase II
clinical trial of MDX-33 in which a new therapy appears to be promising in
treating an increasingly common autoimmune disease, Idiopathic Thrombocytopenia
Purpura (ITP). The data were presented on December 3, 2000, at the Annual
Meeting of the American Society of Hematology in San Francisco, California.
MDX-33 is being developed through a corporate alliance between the Company
and Aventis Behring.
The press release with respect to these clinical trial results is filed
herewith as Exhibit 99.1.
On December 5, 2000, the Company announced that it had showcased its
expanded fully-integrated human antibody technology platform at IBC's Antibody
Engineering Conference. The Company unveiled a unique crossbred mouse developed
in partnership with the pharmaceutical division of Kirin Brewery Co., Ltd. as
the newest addition to the Company's UltiMAb Human Antibody Development
System/SM/.
The press release with respect to this conference presentation is filed
herewith as Exhibit 99.2
This Current Report on Form 8-K contains "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, which represent
the Company's expectations or beliefs concerning future events. Forward-looking
statements involve known and unknown risks and uncertainties and are indicated
by words such as "anticipates", "expects", "believes", "plans", "could" and
similar words and phrases. These risks and uncertainties include, but are not
limited to, uncertainties in obtaining and maintaining regulatory approval,
market acceptance of and continuing demand for the Company's products, the
impact of competitive products and pricing, the Company's ability to obtain
additional financing to support its operations, the continuation of business
partnerships, the progress of ongoing clinical trials, development of new
business opportunities and other risks that may be detailed from time to time in
the Company's
-3-
<PAGE>
periodic reports and registration statements filed with the Securities and
Exchange Commission.
Item 7. Financial Statements and Exhibits.
(c) Exhibits. The following material is filed as an exhibit to
this
Current Report on Form 8-K:
Exhibit
Number Description of Exhibit
------- ----------------------
99.1 Press release dated December 4, 2000.
99.2 Press release dated December 5, 2000.
-4-
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDAREX, INC.
Registrant
Date: December 22, 2000 By:/s/ Donald L. Drakeman
-------------------------------
Donald L. Drakeman
President and Chief Executive
Officer
-5-
<PAGE>
EXHIBIT INDEX
-------------
Exhibit Page
Number Description Number
------- ----------- ------
99.1 Press release dated December 4, 2000.
99.2 Press release dated December 5, 2000.
-6-
